Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide in Relapsed and Refractory Hodgkin's Disease
NCT00005595Phase 2
Key facts
- Status
- Terminated
- Start
- Jun 2000
- Primary completion
- Apr 2002
- Countries
- 1
- Sponsor
- Northwestern University
- Modality
- DNA Intercalators/Alkylators
- Drugs
- arsenic trioxide
- Conditions
- Hodgkin lymphoma (HL)
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in Hodgkin lymphoma (HL), sponsored by Northwestern University. Primary endpoint: Objective Response Rate. Started Jun 2000; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Arsenic Trioxide
Patients receive arsenic trioxide IV
03
Who it enrols
Patients with histologically confirmed relapsed or refractory Hodgkin's disease who have failed at least 2 prior regimens or are refractory to second-line therapy.
04
Endpoints
Primary
Objective Response Rate
Secondary
Duration of Response
Relapse Free Survival
Overall Survival
Toxicities
Beyond the preview
Go deeper on NCT00005595.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005595.